Application 125326

Type
BLA
Sponsor
GLAXO GRP LTD

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
125326Arzerraofatumumab351(a)Disc2026-08-01

Application Products#

Product, Drug, Ingredient table
ProductDrugIngredientFormStrengthReference drugReference standard
001ARZERRAOFATUMUMABINJECTABLE; INJECTION100MG/5MLNoNo
002KESIMPTAOFATUMUMABINJECTABLE;INJECTION20MG/0.4MLNoNo

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
KESIMPTAOFATUMUMABNovartis Pharmaceuticals Corporation6a8a3f53-2062-48ff-9dbe-b939df133ca32026-04-01Warnings, Adverse reactionsExact identifier
application number: BLA125326
ndc (product): 0078-1007

NDC Listings For This Application#

NDC listings for this application page 1 of 1 · 15 matching rows.

NDC, Name, Nonproprietary name table
NDCNameNonproprietary nameLabelerMarketing categoryStatus
0078-0669ARZERRAofatumumabNovartis Pharmaceuticals CorporationBLACurrent
0078-0669ARZERRAofatumumabNovartis Pharmaceuticals CorporationBLACurrent
0078-0669ARZERRAofatumumabNovartis Pharmaceuticals CorporationBLACurrent
0078-0669ARZERRAofatumumabNovartis Pharmaceuticals CorporationBLACurrent
0078-0669ARZERRAofatumumabNovartis Pharmaceuticals CorporationBLACurrent
0078-0690ARZERRAofatumumabNovartis Pharmaceuticals CorporationBLACurrent
0078-0690ARZERRAofatumumabNovartis Pharmaceuticals CorporationBLACurrent
0078-0690ARZERRAofatumumabNovartis Pharmaceuticals CorporationBLACurrent
0078-0690ARZERRAofatumumabNovartis Pharmaceuticals CorporationBLACurrent
0078-0690ARZERRAofatumumabNovartis Pharmaceuticals CorporationBLACurrent
0078-1007KESIMPTAofatumumabNovartis Pharmaceuticals CorporationBLACurrent
0078-1007KESIMPTAofatumumabNovartis Pharmaceuticals CorporationBLACurrent
0078-1007KESIMPTAofatumumabNovartis Pharmaceuticals CorporationBLACurrent
0078-1007KESIMPTAofatumumabNovartis Pharmaceuticals CorporationBLACurrent
0078-1007KESIMPTAofatumumabNovartis Pharmaceuticals CorporationBLACurrent

Documents#

Document, Submission type, Date table
DocumentSubmission typeDate
85632SUPPL 2026-04-02
85631SUPPL 2026-04-02
83153SUPPL 2025-08-20
83152SUPPL 2025-08-20
83134SUPPL 2025-08-19
78139SUPPL 2024-04-15
78132SUPPL 2024-04-15
78014SUPPL 2024-04-01
77269SUPPL 2024-01-23
77253SUPPL 2024-01-22
72040SUPPL2022-09-07
72039SUPPL2022-09-07
72016SUPPL2022-09-06
64359SUPPL2020-08-21
64331SUPPL2020-08-20
64330SUPPL2020-08-20
45215SUPPL2016-08-30
45186SUPPL2016-08-30
31934SUPPL2016-01-21
39931SUPPL2016-01-19
31933SUPPL2014-04-18
18874SUPPL2014-04-17
23951ORIG2013-12-27
18873SUPPL2013-09-27
31932SUPPL2013-09-26
39930SUPPL2011-09-23
9710SUPPL2011-09-23
44801ORIG2010-01-22
43321ORIG2010-01-22
31931ORIG2009-11-02
18872ORIG2009-10-27